Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.37
- Piotroski Score 5.00
- Grade Buy
- Symbol (GOSS)
- Company Gossamer Bio, Inc.
- Price $0.88
- Changes Percentage (-0.81%)
- Change -$0.01
- Day Low $0.86
- Day High $0.90
- Year High $1.60
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $5.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.85
- Trailing P/E Ratio -0.65
- Forward P/E Ratio -0.65
- P/E Growth -0.65
- Net Income $-179,817,000
Income Statement
Quarterly
Annual
Latest News of GOSS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Who Dated Who on 'Gossip Girl'? All About the On-Set Romances During the Show (and Which Leads Dated Each Other IRL!)
Rebecca Aizin, an Associate Editor at PEOPLE since 2023, has contributed to Elle, HGTV, and Backstage....
By PEOPLE.com | 3 days ago -
'Gossip Girl''s Ed Westwick and Wife Amy Jackson Expecting First Baby Together
"Gossip Girl alum Ed Westwick, 37, and actress wife Amy Jackson, 32, are expecting their first baby, just two months after their Italian wedding. The couple shared the news on Instagram, expressing ex...
By PEOPLE.com | 5 days ago -
Confessions of a gossip columnist: we get a bad rap but our salacious tales of the rich and famous play a role in society | Ros Reines
The author reflects on her career as a tabloid gossip columnist in Sydney, navigating personal boundaries and seeking comment from those involved in stories. Despite facing backlash and regret, she ac...
By The Guardian | 2 weeks ago
